{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:33:10Z","timestamp":1790425990628,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jgaronline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jgar.2017.05.019","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T03:01:40Z","timestamp":1500433300000},"page":"295-303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring pathogen"],"prefix":"10.1016","volume":"10","author":[{"given":"A.M.","family":"Bal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.Z.","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Garau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mazzei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tattevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.M.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2017.05.019_bib0005","doi-asserted-by":"crossref","first-page":"e4308","DOI":"10.1371\/journal.pone.0004308","article-title":"Staphylococcus aureus bacteraemia in a tropical setting: patient outcome and impact of antibiotic resistance","volume":"4","author":"Nickerson","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2017.05.019_bib0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/345476","article-title":"Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2017.05.019_bib0015","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/1469-0691.12028","article-title":"The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System","volume":"19","author":"de Kraker","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2017.05.019_bib0020","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1017\/ice.2015.323","article-title":"Determinants of outcome in hospitalized patients with methicillin-resistant Staphylococcus aureus bloodstream infection: results from national surveillance in Canada, 2008\u20132012","volume":"37","author":"Simor","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2017.05.019_bib0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10096-011-1310-2","article-title":"Factors influencing the clinical outcome of methicillin-resistant Staphylococcus aureus bacteraemia","volume":"31","author":"Albur","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2017.05.019_bib0030","doi-asserted-by":"crossref","first-page":"329ra32","DOI":"10.1126\/scitranslmed.aad7364","article-title":"TarO-specific inhibitors of wall teichoic acid biosynthesis restore \u03b2-lactam efficacy against methicillin-resistant staphylococci","volume":"8","author":"Lee","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jgar.2017.05.019_bib0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jgar.2013.01.002","article-title":"Vancomycin in the treatment of meticillin-resistant Staphylococcus aureus (MRSA) infection: end of an era?","volume":"1","author":"Bal","year":"2013","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2017.05.019_bib0040","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jgar.2016.07.010","article-title":"Methicillin-resistant Staphylococcus aureus infections: a review of the currently available treatment options","volume":"7","author":"Purrello","year":"2016","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2017.05.019_bib0045","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2017.05.019_bib0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3410\/M4-4","article-title":"Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates (\u2018the MIC creep\u2019): implications for therapy","volume":"4","author":"Dhand","year":"2012","journal-title":"F1000 Med Rep"},{"key":"10.1016\/j.jgar.2017.05.019_bib0055","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijantimicag.2010.06.044","article-title":"Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates","volume":"36","author":"Campanile","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2017.05.019_bib0060","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1086\/430352","article-title":"Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact","volume":"191","author":"Silverman","year":"2005","journal-title":"J Infect Dis"},{"issue":"Suppl 6","key":"10.1016\/j.jgar.2017.05.019_bib0065","doi-asserted-by":"crossref","first-page":"S678","DOI":"10.1093\/cid\/civ819","article-title":"The regulatory pathway for antifungal drugs: a US perspective","volume":"61","author":"Tillotson","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2017.05.019_bib0070","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2017.05.019_bib0075","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1001\/archinte.163.17.2066","article-title":"Clinical identifiers of complicated Staphylococcus aureus bacteremia","volume":"163","author":"Fowler","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jgar.2017.05.019_bib0080","doi-asserted-by":"crossref","first-page":"7837","DOI":"10.1128\/AAC.02015-15","article-title":"Reduced in vitro activity of ceftaroline by Etest among clonal complex 239 methicillin-resistant Staphylococcus aureus clinical strains from Australia","volume":"59","author":"Abbott","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0085","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.eimc.2015.03.014","article-title":"Executive summary of the diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)","volume":"33","author":"Gudiol","year":"2015","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.jgar.2017.05.019_bib0090","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1128\/AAC.48.8.2871-2875.2004","article-title":"Synergy of daptomycin with oxacillin and other \u03b2-lactams against methicillin-resistant Staphylococcus aureus","volume":"48","author":"Rand","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0095","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cir340","article-title":"Use of antistaphylococcal \u03b2-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding","volume":"53","author":"Dhand","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2017.05.019_bib0100","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3390\/genes6041256","article-title":"Daptomycin-nonsusceptible Staphylococcus aureus: the role of combination therapy with daptomycin and gentamicin","volume":"6","author":"Jiang","year":"2015","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jgar.2017.05.019_bib0105","doi-asserted-by":"crossref","first-page":"e28316","DOI":"10.1371\/journal.pone.0028316","article-title":"Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus","volume":"7","author":"Peleg","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2017.05.019_bib0110","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1128\/IAI.05669-11","article-title":"The Staphylococcus aureus two-component regulatory system, GraRS, senses and confers resistance to selected cationic antimicrobial peptides","volume":"80","author":"Yang","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.jgar.2017.05.019_bib0115","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.02071-15","article-title":"Penicillin binding protein 1 is important in the compensatory response of Staphylococcus aureus to daptomycin-induced membrane damage and is a potential target for \u03b2-lactam\u2013daptomycin synergy","volume":"60","author":"Berti","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0120","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1128\/AAC.02308-12","article-title":"Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic\/pharmacodynamic model: exploring the \u2018seesaw effect\u2019","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0125","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1128\/AAC.01525-12","article-title":"\u03b2-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives","volume":"56","author":"Mehta","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0130","doi-asserted-by":"crossref","first-page":"e42103","DOI":"10.1371\/journal.pone.0042103","article-title":"Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"7","author":"Leonard","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2017.05.019_bib0135","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/AAC.43.7.1747","article-title":"Combinations of vancomycin and \u03b2-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin","volume":"43","author":"Climo","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. A","key":"10.1016\/j.jgar.2017.05.019_bib0140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/29.suppl_A.25","article-title":"The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus","volume":"29","author":"Seibert","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1590\/S0074-02762011000100007","article-title":"Evaluation of the synergistic potential of vancomycin combined with other antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus spp. strains","volume":"106","author":"Silva","year":"2011","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.jgar.2017.05.019_bib0150","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1128\/AAC.01888-13","article-title":"Evaluation of vancomycin in combination with piperacillin\u2013tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus isolates and vancomycin-intermediate S. aureus isolates in vitro","volume":"58","author":"Dilworth","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0155","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1128\/AAC.01204-13","article-title":"\u03b2-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone","volume":"58","author":"Dilworth","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0160","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1128\/AAC.06057-11","article-title":"Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus","volume":"56","author":"Fernandez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0165","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/jac\/dku236","article-title":"Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes","volume":"69","author":"Barber","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0170","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1128\/AAC.00797-12","article-title":"Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity","volume":"56","author":"Rose","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0175","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1128\/AAC.00127-12","article-title":"Efficacy of daptomycin\u2013cloxacillin combination in experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus","volume":"56","author":"Garrigos","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0180","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiw461","article-title":"Redeploying \u03b2-lactam antibiotics as a novel antivirulence strategy for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"215","author":"Waters","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2017.05.019_bib0185","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/civ808","article-title":"Combination of vancomycin and \u03b2-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial","volume":"62","author":"Davis","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2017.05.019_bib0190","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13063-016-1295-3","article-title":"CAMERA2\u2014combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial","volume":"17","author":"Tong","year":"2016","journal-title":"Trials"},{"key":"10.1016\/j.jgar.2017.05.019_bib0195","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2217\/fmb.15.115","article-title":"Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia","volume":"10","author":"Scheeren","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jgar.2017.05.019_bib0200","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"Nicholson","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2017.05.019_bib0205","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.jgar.2017.05.019_bib0210","first-page":"iii19","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 3","key":"10.1016\/j.jgar.2017.05.019_bib0215","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0220","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clinthera.2016.12.005","article-title":"Combination therapy with vancomycin and ceftaroline for refractory methicillin-resistant Staphylococcus aureus bacteremia: a case series","volume":"39","author":"Gritsenko","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.jgar.2017.05.019_bib0225","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s15010-015-0763-0","article-title":"Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature","volume":"43","author":"Baxi","year":"2015","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2017.05.019_bib0230","article-title":"Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"6","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0235","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00097-16","article-title":"Single- and repeated-dose pharmacokinetics of ceftaroline in plasma and soft tissues of healthy volunteers for two different dosing regimens of ceftaroline fosamil","volume":"60","author":"Matzneller","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0240","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s40265-015-0505-8","article-title":"Lipoglycopeptide antibacterial agents in Gram-positive infections: a comparative review","volume":"75","author":"Van Bambeke","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2017.05.019_bib0245","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1742-1241.2007.01318.x","article-title":"Dalbavancin: a novel antimicrobial","volume":"61","author":"Chen","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jgar.2017.05.019_bib0250","first-page":"225","article-title":"New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin","volume":"12","author":"Juul","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jgar.2017.05.019_bib0255","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2017.05.019_bib0260","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2017.05.019_bib0265","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4140\/TCP.n.2016.86","article-title":"Oritavancin: a novel lipoglycopeptide","volume":"31","author":"Mattox","year":"2016","journal-title":"Consult Pharm"},{"key":"10.1016\/j.jgar.2017.05.019_bib0270","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of Gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2017.05.019_bib0275","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2017.05.019_bib0280","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3109\/07853890.2014.935470","article-title":"Renaissance of antibiotics against difficult infections: focus on oritavancin and new ketolides and quinolones","volume":"46","author":"Van Bambeke","year":"2014","journal-title":"Ann Med"},{"key":"10.1016\/j.jgar.2017.05.019_bib0285","doi-asserted-by":"crossref","first-page":"E377","DOI":"10.1111\/1469-0691.12235","article-title":"Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010\u20132011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study","volume":"19","author":"Garau","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2017.05.019_bib0290","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.5301\/ijao.5000008","article-title":"In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers","volume":"34","author":"Kumar","year":"2011","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.jgar.2017.05.019_bib0295","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000316685","article-title":"Modeled dalbavancin transmembrane clearance during intermittent and continuous renal replacement therapies","volume":"30","author":"Vilay","year":"2010","journal-title":"Blood Purif"},{"key":"10.1016\/j.jgar.2017.05.019_bib0300","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.jgar.2017.05.019_bib0305","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/cid\/civ535","article-title":"The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia","volume":"61","author":"Sandrock","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2017.05.019_bib0310","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/1471-2334-14-289","article-title":"A randomized phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study","volume":"14","author":"Stryjewski","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.jgar.2017.05.019_bib0315","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1093\/cid\/civ522","article-title":"Telavancin: the long and winding road from discovery to Food and Drug Administration approvals and future directions","volume":"61","author":"Wenzler","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2017.05.019_bib0320","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijantimicag.2014.12.006","article-title":"The clinical positioning of telavancin in Europe","volume":"45","author":"Masterton","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2017.05.019_bib0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-016-0103-4","article-title":"Oritavancin: a new lipoglycopeptide antibiotic in the treatment of Gram-positive infections","volume":"5","author":"Brade","year":"2016","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2017.05.019_bib0330","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/1871526517666161108130148","article-title":"Use of oritavancin (novel new lipoglycopeptide) in the treatment of prosthetic joint infections (PJI). A possible alternative novel approach to a difficult problem","volume":"17","author":"Antony","year":"2017","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.jgar.2017.05.019_bib0335","doi-asserted-by":"crossref","first-page":"ofv156","DOI":"10.1093\/ofid\/ofv156","article-title":"Prolonged use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis","volume":"2","author":"Johnson","year":"2015","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.jgar.2017.05.019_bib0340","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1093\/cid\/cit618","article-title":"Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary","volume":"58","author":"Das","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2017.05.019_bib0345","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1128\/AAC.03684-14","article-title":"Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function","volume":"59","author":"Flanagan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0350","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.2011.06330.x","article-title":"The oxazolidinones: past, present, and future","volume":"1241","author":"Shaw","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jgar.2017.05.019_bib0355","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2017.05.019_bib0360","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6days versus linezolid for 10days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2017.05.019_bib0365","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/AAC.03688-14","article-title":"Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections","volume":"59","author":"Shorr","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0370","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/jac\/dkv300","article-title":"Susceptibility of Clostridium difficile isolates from a phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection","volume":"71","author":"Gerding","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0375","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1128\/AAC.01723-09","article-title":"Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils","volume":"54","author":"Lemaire","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0380","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2017.05.019_bib0385","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.01614-13","article-title":"Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections","volume":"58","author":"Solomkin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0390","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02411-16","article-title":"Activities of omadacycline and comparator agents against Staphylococcus aureus isolates from a surveillance program conducted in North America and Europe","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0395","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1128\/AAC.00948-12","article-title":"A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections","volume":"56","author":"Noel","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0400","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2217\/fmb-2016-0100","article-title":"Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections","volume":"11","author":"Villano","year":"2016","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jgar.2017.05.019_bib0405","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-Gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0410","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/jac\/dkv411","article-title":"A randomized, double-blind, phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin","volume":"71","author":"Kingsley","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0415","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijid.2014.10.009","article-title":"A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections","volume":"30","author":"O\u2019Riordan","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2017.05.019_bib0420","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/fmb.15.39","article-title":"Delafloxacin, a non-zwitterionic fluoroquinolone in phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy","volume":"10","author":"Van Bambeke","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jgar.2017.05.019_bib0425","doi-asserted-by":"crossref","first-page":"E1562","DOI":"10.3390\/molecules21111562","article-title":"Antimicrobial activity of zabofloxacin against clinically isolated Streptococcus pneumoniae","volume":"21","author":"Park","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.jgar.2017.05.019_bib0430","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12941-016-0150-4","article-title":"Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin","volume":"15","author":"Kocsis","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jgar.2017.05.019_bib0435","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1128\/CMR.00049-15","article-title":"Decolonization in prevention of health care-associated infections","volume":"29","author":"Septimus","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2017.05.019_bib0440","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/jac\/dkv442","article-title":"Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid","volume":"71","author":"Zeitlinger","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0445","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1128\/AAC.02106-12","article-title":"Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections","volume":"57","author":"Prince","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0450","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1749-6632.2011.06219.x","article-title":"Are pleuromutilin antibiotics finally fit for human use?","volume":"1241","author":"Novak","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jgar.2017.05.019_bib0455","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0968-0896(00)00338-2","article-title":"Pleuromutilins. Part 1. The identification of novel mutilin 14-carbamates","volume":"9","author":"Brooks","year":"2001","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jgar.2017.05.019_bib0460","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1128\/AAC.00131-06","article-title":"The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics","volume":"50","author":"Long","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0465","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/cid\/cix272","article-title":"Telavancin in the recent hospital acquired and ventilator associated pneumonia (HAP\/VAP) 2016 guideline","volume":"64","author":"Hassoun","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2017.05.019_bib0470","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/jac\/dkp058","article-title":"Vinaxanthone, a new FabI inhibitor from Penicillium sp","volume":"63","author":"Zheng","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2017.05.019_bib0475","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/ja.2013.49","article-title":"Prospects for new antibiotics: a molecule-centered perspective","volume":"67","author":"Walsh","year":"2014","journal-title":"J Antibiot (Tokyo)"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517301066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517301066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T21:12:33Z","timestamp":1569877953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716517301066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":95,"alternative-id":["S2213716517301066"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2017.05.019","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring pathogen","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2017.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}